MX2009004986A - Metodos de tratamiento de anemia hemolitica. - Google Patents

Metodos de tratamiento de anemia hemolitica.

Info

Publication number
MX2009004986A
MX2009004986A MX2009004986A MX2009004986A MX2009004986A MX 2009004986 A MX2009004986 A MX 2009004986A MX 2009004986 A MX2009004986 A MX 2009004986A MX 2009004986 A MX2009004986 A MX 2009004986A MX 2009004986 A MX2009004986 A MX 2009004986A
Authority
MX
Mexico
Prior art keywords
methods
hemolytic anemia
treating hemolytic
treating
complement
Prior art date
Application number
MX2009004986A
Other languages
English (en)
Inventor
Russell P Rother
Leonard Bell
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of MX2009004986A publication Critical patent/MX2009004986A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La hemoglobinuria paroxística nocturna u otras enfermedades hemolíticas son tratadas utilizando un compuesto que se enlaza o bloquea de otra manera la generación y/o la actividad de uno o más componentes de complemento, tales como por ejemplo, un anticuerpo inhibidor de complemento.
MX2009004986A 2006-11-08 2007-11-08 Metodos de tratamiento de anemia hemolitica. MX2009004986A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/595,118 US20070116710A1 (en) 2004-02-03 2006-11-08 Methods of treating hemolytic anemia
PCT/US2007/023623 WO2008069889A2 (en) 2006-11-08 2007-11-08 Methods of treating hemolytic anemia

Publications (1)

Publication Number Publication Date
MX2009004986A true MX2009004986A (es) 2009-05-21

Family

ID=39326944

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004986A MX2009004986A (es) 2006-11-08 2007-11-08 Metodos de tratamiento de anemia hemolitica.

Country Status (10)

Country Link
US (1) US20070116710A1 (es)
EP (1) EP2089058A2 (es)
JP (1) JP2010509338A (es)
KR (1) KR20090076960A (es)
AU (1) AU2007328435B2 (es)
BR (1) BRPI0718830A2 (es)
CA (1) CA2669735A1 (es)
IL (1) IL198320A0 (es)
MX (1) MX2009004986A (es)
WO (1) WO2008069889A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140057635A (ko) 2006-03-15 2014-05-13 알렉시온 파마슈티칼스, 인코포레이티드 보체의 저해물질로 발작성 야간혈색뇨증 환자의 치료
WO2007114319A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 抗体の血中動態を制御する方法
HUE026042T2 (en) 2006-10-10 2016-05-30 Regenesance B V Complement inhibition for improved nerve regeneration
CN101809154A (zh) * 2007-09-24 2010-08-18 诺松制药股份公司 C5a结合核酸
JP5334319B2 (ja) 2007-09-26 2013-11-06 中外製薬株式会社 Ｃｄｒのアミノ酸置換により抗体の等電点を改変する方法
CA2712724A1 (en) * 2008-01-29 2009-08-06 Celgene Corporation Use of lenalidomide or pomalidomide for treating a disease associated with cd59 deficiency
PL2708558T3 (pl) 2008-04-11 2018-09-28 Chugai Seiyaku Kabushiki Kaisha Cząsteczka wiążąca antygen zdolna do wiązania dwóch lub więcej cząsteczek antygenu w sposób powtarzalny
RS54113B1 (en) 2008-08-05 2015-12-31 Novartis Ag COMPOSITIONS AND PROCEDURES FOR ANTIBODIES ON THE C5 COMPLEMENTARY PROTEIN
EP3101031A1 (en) * 2008-11-10 2016-12-07 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
IN2012DN04412A (es) 2009-11-09 2015-08-07 Alexion Pharmaceuticals Inc
WO2012073992A1 (ja) 2010-11-30 2012-06-07 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
US9051365B2 (en) 2011-12-21 2015-06-09 Novartis Ag Antibodies that bind factor P
WO2013104540A1 (en) 2012-01-10 2013-07-18 Noxxon Pharma Ag New c5a binding nucleic acids
WO2015039126A1 (en) * 2013-09-16 2015-03-19 Children hospital medical center Compositions and methods for treatment of hsct-associated thrombotic microangiopathy
SI3233921T1 (sl) 2014-12-19 2022-01-31 Chugai Seiyaku Kabushiki Kaisha Protitelesa proti C5 in postopki za uporabo
EP3247723A1 (en) 2015-01-22 2017-11-29 Chugai Seiyaku Kabushiki Kaisha A combination of two or more anti-c5 antibodies and methods of use
EP3307318A4 (en) 2015-06-09 2019-01-16 Children's Hospital Medical Center DOSAGE ALGORITHM FOR COMPLEMENT INHIBITOR
CN116769024A (zh) 2016-06-14 2023-09-19 瑞泽恩制药公司 抗c5抗体及其用途
MX2019001448A (es) 2016-08-05 2019-09-13 Chugai Pharmaceutical Co Ltd Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8).
IT201600121482A1 (it) * 2016-11-30 2018-05-30 Univ Degli Studi Di Verona Fattore H per l’uso nel trattamento e/o prevenzione della formazione di eterotrombi in pazienti affetti da anemia falciforme
BR112019015426A2 (pt) 2017-01-31 2020-05-26 Chugai Seiyaku Kabushiki Kaisha Composição farmacêutica para uso no tratamento ou prevenção de uma doença relacionada a c5 e um método para tratar ou prevenir uma doença rela-cionada a c5
WO2019118556A1 (en) 2017-12-13 2019-06-20 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
BR112021001655A2 (pt) 2018-08-01 2021-05-04 Chugai Seiyaku Kabushiki Kaisha composição farmacêutica para uso no tratamento ou prevenção de uma doença relacionada a c5 e método para tratar ou prevenir uma doença relacionada a c5
KR20240033090A (ko) 2019-07-31 2024-03-12 에프. 호프만-라 로슈 아게 항-c5 항체 크로발리맙의 사용에 의한 c5-관련 질병의 치료 또는 예방을 위한 투여량 및 투여 섭생
EP4003408A1 (en) 2019-07-31 2022-06-01 F. Hoffmann-La Roche AG Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab
JP2023522208A (ja) 2020-04-16 2023-05-29 アシスタンス ピュブリック－オピト ド パリ ウイルスによって引き起こされる補体媒介性障害を処置する方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686100A (en) * 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
US5135916A (en) * 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
AU2002234001B2 (en) * 2000-12-05 2008-05-01 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US7361339B2 (en) * 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease

Also Published As

Publication number Publication date
WO2008069889A9 (en) 2008-09-18
KR20090076960A (ko) 2009-07-13
AU2007328435A1 (en) 2008-06-12
WO2008069889A2 (en) 2008-06-12
EP2089058A2 (en) 2009-08-19
IL198320A0 (en) 2011-08-01
US20070116710A1 (en) 2007-05-24
BRPI0718830A2 (pt) 2014-02-04
CA2669735A1 (en) 2008-06-12
AU2007328435B2 (en) 2013-03-07
JP2010509338A (ja) 2010-03-25
WO2008069889A3 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
MX2009004986A (es) Metodos de tratamiento de anemia hemolitica.
EP2520311A3 (en) Method of treating hemolytic disease
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
NO20083153L (no) Kjemiske forbindelser
MX2010004219A (es) Agentes de enlace de cd19 y usos de los mismos.
MX360301B (es) Moleculas pequeñas que contienen boro como agentes antiinflamatorios.
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
EA200802428A1 (ru) Комбинации агентов для биологической борьбы и нематоцидов, входящих в покрытие семян
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
SG170813A1 (en) New compounds
WO2007140002A3 (en) Method for treating non-hodgkin's lymphoma
MX2008007307A (es) Granulos/capsulas modificados que contienen ingrediente activo.
TW200716624A (en) Compounds for modulating TRPV3 function
MX2009005455A (es) (r)-n-estereoisomeros de analogos de 7,8-saturados-4,5 epoxi-morfinano.
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
CY1110209T1 (el) Υποκατεστημενες ενωσεις βενζο(d)ισοξαζολ-3-υλ-αμινης σαν αναλγητικα
EA200601766A1 (ru) Производные имидазола
TW200603728A (en) A method for treating plants or plant parts
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
MX2010006823A (es) Metodos para el tratamiento de la gota.
MY150602A (en) Subtituted-quinoxaline-type piperidine compounds and the uses thereof
ATE488232T1 (de) P53 aktivierende benzoylharnstoff- und benzoylthioharnstoff-verbindungen
EP2425849A3 (en) Compositions and methods using anti-CS1 antibodies to treat multiple myeloma
UA92894C2 (ru) Способ приготовления и применения композиции адсорбента фосфата, адсорбент фосфата, композиция адсорбента фосфата
TW200800967A (en) Benzimidazole thiophene compounds

Legal Events

Date Code Title Description
FA Abandonment or withdrawal